[go: up one dir, main page]

DE69921611D1 - Verbindungen mit wachstumshormon-freisetzenden eigenschaften - Google Patents

Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Info

Publication number
DE69921611D1
DE69921611D1 DE69921611T DE69921611T DE69921611D1 DE 69921611 D1 DE69921611 D1 DE 69921611D1 DE 69921611 T DE69921611 T DE 69921611T DE 69921611 T DE69921611 T DE 69921611T DE 69921611 D1 DE69921611 D1 DE 69921611D1
Authority
DE
Germany
Prior art keywords
growth hormone
connections
hormone releasing
releasing properties
properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69921611T
Other languages
English (en)
Other versions
DE69921611T2 (de
Inventor
Michael Ankersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Therapeutics US Inc
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE69921611D1 publication Critical patent/DE69921611D1/de
Publication of DE69921611T2 publication Critical patent/DE69921611T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE69921611T 1998-01-16 1999-01-15 Verbindungen mit wachstumshormon-freisetzenden eigenschaften Expired - Lifetime DE69921611T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DK5698 1998-01-16
DK5698 1998-01-16
DK79998 1998-06-15
DK79998 1998-06-15
PCT/DK1999/000021 WO1999036431A1 (en) 1998-01-16 1999-01-15 Compounds with growth hormone releasing properties

Publications (2)

Publication Number Publication Date
DE69921611D1 true DE69921611D1 (de) 2004-12-09
DE69921611T2 DE69921611T2 (de) 2005-11-03

Family

ID=26063207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69921611T Expired - Lifetime DE69921611T2 (de) 1998-01-16 1999-01-15 Verbindungen mit wachstumshormon-freisetzenden eigenschaften

Country Status (15)

Country Link
EP (2) EP1047709B1 (de)
JP (1) JP4382279B2 (de)
KR (1) KR20010034198A (de)
CN (1) CN1288467A (de)
AT (2) ATE470671T1 (de)
AU (1) AU766305B2 (de)
BR (1) BR9906975A (de)
CA (1) CA2318558A1 (de)
DE (1) DE69921611T2 (de)
HU (1) HUP0100777A3 (de)
IL (1) IL137007A0 (de)
NO (1) NO20003629L (de)
PL (1) PL341707A1 (de)
TW (1) TW589325B (de)
WO (1) WO1999036431A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CN102584937B (zh) * 2004-06-29 2017-03-01 赫尔辛医疗股份公司 (3r)‑1‑(2‑甲基丙氨酰‑d‑色氨酰)‑3‑(苯甲基)‑3‑哌啶羧酸1，2，2‑三甲基酰肼的晶形
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
CN108129357B (zh) * 2016-12-01 2021-12-21 上海医药工业研究院 阿拉莫林中间体的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8005121A (nl) * 1979-09-20 1981-03-24 Erba Farmitalia Biologisch actieve peptiden.
WO1983002272A1 (en) 1981-12-28 1983-07-07 Beckman Instruments Inc Synthetic peptides having pituitary growth hormone releasing activity
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
WO1989010933A1 (en) 1988-05-11 1989-11-16 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
IT1240643B (it) 1990-05-11 1993-12-17 Mediolanum Farmaceutici Spa Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL98910A0 (en) 1990-07-24 1992-07-15 Polygen Holding Corp Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
EP0730578A4 (de) 1993-11-24 1997-10-08 Merck & Co Inc Indolyl-gruppen enthaltende verbindungen und deren verwendung zur förderung der freisetzung von wachstumshormonen
UA45962C2 (uk) 1993-12-23 2002-05-15 Ново Нордіск А/С Похідні пептидів, фармацевтична композиція,спосіб стимулювання секреції гормону росту з гіпофізу
IL112112A (en) 1993-12-23 2000-06-29 Novo Nordisk As Peptides with growth hormone releasing properties and pharmaceutical compositions containing them
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
WO1996002530A1 (en) 1994-07-20 1996-02-01 Merck & Co., Inc. Piperidines and hexahydro-1h-azepines spiro substituted at the 4-position promote release of growth hormone
US5767118A (en) 1994-10-26 1998-06-16 Merck & Co., Inc. 4-Heterocyclic peperidines promote release of growth hormone
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
IL116923A (en) 1995-01-27 2000-09-28 Novo Nordisk As Compounds with growth hormone releasing properties and pharmaceutical compositions containing them
US5559128A (en) 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (de) 1995-05-29 2005-02-02 Pfizer Inc. Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
CZ287948B6 (cs) 1995-06-22 2001-03-14 Novo Nordisk A/S Peptidový derivát uvolňující růstový hormon, farmaceutický prostředek s jeho obsahem a jejich použití
CA2203428A1 (en) 1995-08-21 1997-02-27 Philip Arthur Hipskind 2-acylaminopropanamides as growth hormone secretagogues
WO1997007117A1 (en) 1995-08-21 1997-02-27 Eli Lilly And Company 2-acylaminopropanamines as growth hormone secretagogues
EP0766966A3 (de) 1995-09-08 2001-02-28 Eli Lilly And Company Methode zur Behandlung der Insulinresistenz
AU7169696A (en) 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
IT1277113B1 (it) 1995-12-20 1997-11-04 Romano Deghenghi Composti oligopeptidici contenenti d-2-alchiltriptofano in grado di promuovere la liberazione dell'ormone della crescita
BR9612275A (pt) 1995-12-22 1999-07-13 Novo Nordisk As Composto composição farmacêutica processo para estimular a liberação do hormônio do crescimento pela pituitária e aumentar a taxa e a extensão do crescimento da produção do leite e lã ou para tratar doenças e uso de um composto
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
AU2334097A (en) 1996-03-21 1997-10-10 Merck & Co., Inc. 4-spiroindoline piperidines promote release of growth hormone
EP1005484A1 (de) * 1997-06-20 2000-06-07 Novo Nordisk A/S Verbindungen mit wachstumshormon freisetzenden eigenschaften

Also Published As

Publication number Publication date
NO20003629D0 (no) 2000-07-14
EP1047709A1 (de) 2000-11-02
PL341707A1 (en) 2001-04-23
CA2318558A1 (en) 1999-07-22
WO1999036431A1 (en) 1999-07-22
ATE281467T1 (de) 2004-11-15
AU2046599A (en) 1999-08-02
IL137007A0 (en) 2001-06-14
HUP0100777A3 (en) 2001-12-28
JP4382279B2 (ja) 2009-12-09
EP1506969B1 (de) 2010-06-09
AU766305B2 (en) 2003-10-16
EP1506969A1 (de) 2005-02-16
EP1047709B1 (de) 2004-11-03
BR9906975A (pt) 2000-10-17
TW589325B (en) 2004-06-01
CN1288467A (zh) 2001-03-21
HUP0100777A2 (hu) 2001-08-28
ATE470671T1 (de) 2010-06-15
DE69921611T2 (de) 2005-11-03
JP2002509156A (ja) 2002-03-26
KR20010034198A (ko) 2001-04-25
WO1999036431A9 (en) 2000-07-27
NO20003629L (no) 2000-09-15

Similar Documents

Publication Publication Date Title
ATE344063T1 (de) Beschichtete medizinische geräte
SE9900100D0 (sv) New compounds
ATE248837T1 (de) Chinuclidin-acrylamide
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DK1137410T3 (da) Hidtil ukendte 4-dedimethylaminotetracyclinderivater
DE69941255D1 (de) Verbindungen mit wachstumshormon freisetzenden eigenschaften
DE69623899D1 (de) Behandlung von Tinnitus mit neuroprotektiven Wirkstoffen
DE60036826D1 (de) Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs
DE69718469D1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DE69318821D1 (de) Katheter zur Versorgung des Penis mit Medikamenten
DE69921611D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DE69943239D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
ES2102772T3 (es) Compuesto citotoxico y antiviral.
ID25478A (id) Agonis 5-ht1f
DE19983519T1 (de) Vorrichtung zur Wärmebehandlung von Körpergewebe
DE69419661D1 (de) Thiazolotriazol- und Thiazolodiazolderivate mit fungizider Aktivität
NO20012169D0 (no) Forbindelser med veksthormonfrigjörende egenskaper
FI117320B (fi) Bradykiniiniantagonistien käyttö lääkeaineiden valmistamiseksi virussairauksien hoitamiseksi
ATE80800T1 (de) Verwendung von suramin und physiologisch vertraeglichen derivaten davon, gegebenenfalls in kombination mit anti-androgenen mitteln zur herstellung von arzneimitteln zur behandlung des humanen prostatakarzinoms.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SAPPHIRE THERAPEUTICS, INC., BRIDGEWATER, N.J., US